Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial of the Combination of Atezolizumab With Dendritic Cell Vaccination as Maintenance Treatment in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Induction Treatment

NCT04487756 is registered in ClinicalTrials.gov with Instituto Oncológico Dr Rosell as lead sponsor.

NCT NCT04487756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04487756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial of the Combination of Atezolizumab With Dendritic Cell Vaccination as Maintenance Treatment in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Induction Treatment
Lead sponsor
Instituto Oncológico Dr Rosell
Phase
Phase 1/2
Overall status
Completed
Start date
March 17, 2021
Completion date
September 8, 2025
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer